Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer.

Aula H, Skyttä T, Tuohinen S, Luukkaala T, Hämäläinen M, Virtanen V, Raatikainen P, Moilanen E, Kellokumpu-Lehtinen PL.

Radiat Oncol. 2018 Oct 19;13(1):201. doi: 10.1186/s13014-018-1150-7.

2.

Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage.

Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen PL.

Contrast Media Mol Imaging. 2018 Sep 19;2018:3181258. doi: 10.1155/2018/3181258. eCollection 2018.

3.

T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.

Leivonen SK, Pollari M, Brück O, Pellinen T, Autio M, Karjalainen-Lindsberg ML, Mannisto S, Kellokumpu-Lehtinen PL, Kallioniemi O, Mustjoki S, Leppä S.

Haematologica. 2018 Sep 20. pii: haematol.2018.200105. doi: 10.3324/haematol.2018.200105. [Epub ahead of print]

4.

ANO7 is associated with aggressive prostate cancer.

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL; PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J.

Int J Cancer. 2018 Nov 15;143(10):2479-2487. doi: 10.1002/ijc.31746. Epub 2018 Sep 22.

PMID:
30157291
5.

PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.

Pollari M, Brück O, Pellinen T, Vähämurto P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O, Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK, Leppä S.

Haematologica. 2018 Nov;103(11):1908-1914. doi: 10.3324/haematol.2018.197194. Epub 2018 Jul 19.

6.

Does special education in palliative medicine make a difference in end-of-life decision-making?

Piili RP, Lehto JT, Luukkaala T, Hinkka H, Kellokumpu-Lehtinen PI.

BMC Palliat Care. 2018 Jul 18;17(1):94. doi: 10.1186/s12904-018-0349-6.

7.

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H.

JAMA Oncol. 2018 Sep 1;4(9):1199-1206. doi: 10.1001/jamaoncol.2018.1380.

8.

Changes in attitudes towards hastened death among Finnish physicians over the past sixteen years.

Piili RP, Metsänoja R, Hinkka H, Kellokumpu-Lehtinen PI, Lehto JT.

BMC Med Ethics. 2018 May 30;19(1):40. doi: 10.1186/s12910-018-0290-5.

9.

Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.

Tuohinen SS, Keski-Pukkila K, Skyttä T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen PL, Raatikainen P, Nikus K.

Anticancer Res. 2018 Apr;38(4):2207-2215.

PMID:
29599341
10.

p95HER2 Methionine 611 Carboxy-Terminal Fragment Is Predictive of Trastuzumab Adjuvant Treatment Benefit in the FinHer Trial.

Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie YS, Petropoulos CJ, Weidler J, Joensuu H.

Clin Cancer Res. 2018 Jul 1;24(13):3046-3052. doi: 10.1158/1078-0432.CCR-17-3250. Epub 2018 Mar 13.

PMID:
29535130
11.

Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population.

Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, Lebrecht A, Battista MJ, Hasenburg A, Sahin U, Kalogeras KT, Kellokumpu-Lehtinen PL, Fountzilas G, Wirtz RM, Joensuu H.

Breast Cancer Res. 2018 Feb 26;20(1):15. doi: 10.1186/s13058-018-0942-x.

12.

Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.

Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12.

Eur Urol. 2018 Jun;73(6):870-876. doi: 10.1016/j.eururo.2018.01.012. Epub 2018 Feb 1.

PMID:
29395502
13.

Natural Killer Cell Viability After Hyperthermia Alone or Combined with Radiotherapy with or without Cytokines.

Hietanen T, Kapanen M, Kellokumpu-Lehtinen PL.

Anticancer Res. 2018 Feb;38(2):655-663.

PMID:
29374687
14.

Adjuvant Breast Cancer Treatments Induce Changes in Homoarginine Level - A Prospective Observational Study.

Aula H, Skyttä T, Tuohinen S, Luukkaala T, Hämäläinen M, Virtanen V, Raatikainen P, Moilanen E, Kellokumpu-Lehtinen PL.

Anticancer Res. 2017 Dec;37(12):6815-6824.

PMID:
29187460
15.

Associations between ECG changes and echocardiographic findings in patients with acute non-ST elevation myocardial infarction.

Tuohinen SS, Rankinen J, Skyttä T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen PL, Raatikainen P, Nikus K.

J Electrocardiol. 2018 Mar - Apr;51(2):188-194. doi: 10.1016/j.jelectrocard.2017.11.007. Epub 2017 Nov 21.

PMID:
29174705
16.

Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.

Pajamäki N, Metso S, Hakala T, Ebeling T, Huhtala H, Ryödi E, Sand J, Jukkola-Vuorinen A, Kellokumpu-Lehtinen PL, Jaatinen P.

Clin Endocrinol (Oxf). 2018 Feb;88(2):303-310. doi: 10.1111/cen.13519. Epub 2017 Dec 14.

PMID:
29154445
17.

Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer.

Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen PL.

Anticancer Res. 2017 Sep;37(9):5027-5032.

PMID:
28870929
18.

CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, José V, Pommey S, Delisle V, Loi S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Smyth MJ, Stagg J.

Cancer Res. 2017 Oct 15;77(20):5652-5663. doi: 10.1158/0008-5472.CAN-17-0707. Epub 2017 Aug 30.

19.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

20.

High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.

Väänänen T, Kallio J, Vuolteenaho K, Ojala A, Luukkaala T, Hämäläinen M, Tammela T, Kellokumpu-Lehtinen PL, Moilanen E.

Scand J Urol. 2017 Oct;51(5):367-372. doi: 10.1080/21681805.2017.1327885. Epub 2017 Jun 23.

PMID:
28644702
21.

Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.

Kallio J, Hämäläinen M, Luukkaala T, Moilanen E, Tammela TL, Kellokumpu-Lehtinen PL.

Urol Oncol. 2017 Sep;35(9):544.e25-544.e31. doi: 10.1016/j.urolonc.2017.05.005. Epub 2017 May 29.

PMID:
28572026
22.

Effects of multiple breath hold reproducibility on treatment localization and dosimetric accuracy in radiotherapy of left-sided breast cancer with voluntary deep inspiration breath hold technique.

Kapanen M, Laaksomaa M, Pehkonen J, Haltamo M, Luukkanen H, Lehtonen T, Hyödynmaa S, Kellokumpu-Lehtinen PL.

Med Dosim. 2017 Autumn;42(3):177-184. doi: 10.1016/j.meddos.2017.02.004. Epub 2017 May 16.

PMID:
28526193
23.

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Lahdenperä O, Kosonen S, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Junnila J, Bono P, Lindman H.

JAMA Oncol. 2017 Jun 1;3(6):793-800. doi: 10.1001/jamaoncol.2016.6120.

24.

Detection of early radiotherapy-induced changes in intrinsic myocardial contractility by ultrasound tissue characterization in patients with early-stage breast cancer.

Tuohinen SS, Skyttä T, Huhtala H, Virtanen V, Virtanen M, Kellokumpu-Lehtinen PL, Raatikainen P.

Echocardiography. 2017 Feb;34(2):191-198. doi: 10.1111/echo.13433.

PMID:
28240428
25.

The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy.

Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL.

Mol Imaging Biol. 2017 Oct;19(5):787-794. doi: 10.1007/s11307-017-1044-3.

PMID:
28144908
26.

Undergraduate curriculum in palliative medicine at Tampere University increases students' knowledge.

Lehto JT, Hakkarainen K, Kellokumpu-Lehtinen PL, Saarto T.

BMC Palliat Care. 2017 Jan 25;16(1):13. doi: 10.1186/s12904-016-0182-8.

27.

Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.

Tiainen L, Tanner M, Lahdenperä O, Vihinen P, Jukkola A, Karihtala P, Paunu N, Huttunen T, Kellokumpu-Lehtinen PL.

Anticancer Res. 2016 Dec;36(12):6431-6438.

PMID:
27919965
28.

Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study.

Tuohinen SS, Skyttä T, Poutanen T, Huhtala H, Virtanen V, Kellokumpu-Lehtinen PL, Raatikainen P.

Int J Cardiovasc Imaging. 2017 Apr;33(4):463-472. doi: 10.1007/s10554-016-1021-y. Epub 2016 Nov 21.

PMID:
27873127
29.

Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer.

Wu X, Reinikainen P, Vanhanen A, Kapanen M, Vierikko T, Ryymin P, Hyödynmaa S, Kellokumpu-Lehtinen PL.

Diagn Interv Imaging. 2017 Jan;98(1):63-71. doi: 10.1016/j.diii.2016.08.009. Epub 2016 Sep 27.

30.

Novel Angiogenesis Markers as Long-Term Prognostic Factors in Patients With Renal Cell Cancer.

Lampinen AM, Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Saharinen P, Kellokumpu-Lehtinen PI.

Clin Genitourin Cancer. 2017 Feb;15(1):e15-e24. doi: 10.1016/j.clgc.2016.07.008. Epub 2016 Jul 21.

PMID:
27554585
31.

Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.

Kaukonen R, Mai A, Georgiadou M, Saari M, De Franceschi N, Betz T, Sihto H, Ventelä S, Elo L, Jokitalo E, Westermarck J, Kellokumpu-Lehtinen PL, Joensuu H, Grenman R, Ivaska J.

Nat Commun. 2016 Aug 4;7:12237. doi: 10.1038/ncomms12237.

32.

Treatment accuracy without rotational setup corrections in intracranial SRT.

Boman E, Kapanen M, Laaksomaa M, Mäenpää H, Hyödynmaa S, Kellokumpu-Lehtinen PL.

J Appl Clin Med Phys. 2016 Jul 8;17(4):86-94. doi: 10.1120/jacmp.v17i4.6149.

33.

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.

Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P, Turpeenniemi-Hujanen T, Jyrkkiö S, Lakis S, Schlombs K, Laible M, Weber S, Eidt S, Sahin U, Joensuu H.

Breast Cancer Res Treat. 2016 Jun;157(3):437-46. doi: 10.1007/s10549-016-3835-7. Epub 2016 May 24.

34.

Health-related Quality of Life in Breast Cancer Patients after Adjuvant Treatments.

Roine E, Blomqvist C, Kellokumpu-Lehtinen PL, Sintonen H, Saarto T.

Breast J. 2016 Jul;22(4):473-5. doi: 10.1111/tbj.12613. Epub 2016 Apr 28. No abstract available.

PMID:
27124555
35.

Improving the reproducibility of voluntary deep inspiration breath hold technique during adjuvant left-sided breast cancer radiotherapy.

Skyttä T, Kapanen M, Laaksomaa M, Peltola S, Haltamo M, Boman E, Hyödynmaa S, Kellokumpu-Lehtinen PL.

Acta Oncol. 2016 Aug;55(8):970-5. doi: 10.3109/0284186X.2016.1161823. Epub 2016 Apr 12.

PMID:
27070120
36.

Differentiation of Diffuse Large B-cell Lymphoma From Follicular Lymphoma Using Texture Analysis on Conventional MR Images at 3.0 Tesla.

Wu X, Sikiö M, Pertovaara H, Järvenpää R, Eskola H, Dastidar P, Kellokumpu-Lehtinen PL.

Acad Radiol. 2016 Jun;23(6):696-703. doi: 10.1016/j.acra.2016.01.012. Epub 2016 Mar 11.

PMID:
26976622
37.

Restoring Natural Killer Cell Cytotoxicity After Hyperthermia Alone or Combined with Radiotherapy.

Hietanen T, Kapanen M, Kellokumpu-Lehtinen PL.

Anticancer Res. 2016 Feb;36(2):555-63.

PMID:
26851009
38.

Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

Virman JP, Bono P, Luukkaala TH, Sunela KL, Kujala PM, Kellokumpu-Lehtinen PL.

Clin Genitourin Cancer. 2016 Aug;14(4):e283-9. doi: 10.1016/j.clgc.2015.12.014. Epub 2015 Dec 22.

39.

Detection of radiotherapy-induced myocardial changes by ultrasound tissue characterisation in patients with breast cancer.

Tuohinen SS, Skyttä T, Virtanen V, Virtanen M, Luukkaala T, Kellokumpu-Lehtinen PL, Raatikainen P.

Int J Cardiovasc Imaging. 2016 May;32(5):767-76. doi: 10.1007/s10554-016-0837-9. Epub 2016 Jan 12.

PMID:
26757708
40.

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ.

Cancer Res. 2016 Jan 15;76(2):264-74. doi: 10.1158/0008-5472.CAN-15-1567. Epub 2016 Jan 7.

41.

Post-irradiation viability and cytotoxicity of natural killer cells isolated from human peripheral blood using different methods.

Hietanen T, Pitkänen M, Kapanen M, Kellokumpu-Lehtinen PL.

Int J Radiat Biol. 2016;92(2):71-9. doi: 10.3109/09553002.2016.1115136. Epub 2015 Dec 3.

PMID:
26634866
42.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H.

Lancet Oncol. 2015 Dec;16(16):1700-10. doi: 10.1016/S1470-2045(15)00373-3. Epub 2015 Nov 17.

PMID:
26596672
43.

Residual position errors of lymph node surrogates in breast cancer adjuvant radiotherapy: Comparison of two arm fixation devices and the effect of arm position correction.

Kapanen M, Laaksomaa M, Skyttä T, Haltamo M, Pehkonen J, Lehtonen T, Kellokumpu-Lehtinen PL, Hyödynmaa S.

Med Dosim. 2016 Spring;41(1):47-52. doi: 10.1016/j.meddos.2015.08.001. Epub 2015 Oct 9.

PMID:
26482907
44.

Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.

Hakala TT, Sand JA, Jukkola A, Huhtala HS, Metso S, Kellokumpu-Lehtinen PL.

Int J Clin Oncol. 2016 Apr;21(2):231-239. doi: 10.1007/s10147-015-0904-6. Epub 2015 Sep 26.

PMID:
26410770
45.

Effects of Single and Fractionated Irradiation on Natural Killer Cell Populations: Radiobiological Characteristics of Viability and Cytotoxicity In Vitro.

Hietanen T, Pitkänen M, Kapanen M, Kellokumpu-Lehtinen PL.

Anticancer Res. 2015 Oct;35(10):5193-200.

PMID:
26408677
46.

Human breast cancer cells educate macrophages toward the M2 activation status.

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J, Kellokumpu-Lehtinen PL, Lauttia S, Tynninen O, Joensuu H, Heymann D, Määttä JA.

Breast Cancer Res. 2015 Aug 5;17:101. doi: 10.1186/s13058-015-0621-0.

47.

[Cardiac effects of radiation therapy].

Tuohinen S, Turpeinen A, Skyttä T, Kellokumpu-Lehtinen PL.

Duodecim. 2015;131(5):433-40. Review. Finnish.

PMID:
26237905
48.

Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.

Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Van den Eynden G, Rothé F, Desmedt C, Neven P, Loibl S, Denkert C, Joensuu H, Loi S, Sirtaine N, Kellokumpu-Lehtinen PL, Piccart M, Sotiriou C.

BMC Med. 2015 Aug 3;13:177. doi: 10.1186/s12916-015-0416-2.

49.

Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy.

Skyttä T, Tuohinen S, Boman E, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL.

Radiat Oncol. 2015 Jul 10;10:141. doi: 10.1186/s13014-015-0436-2.

50.

Effects of remedies made in patient setup process on residual setup errors and margins in head and neck cancer radiotherapy based on 2D image guidance.

Kapanen M, Laaksomaa M, Tulijoki T, Kellokumpu-Lehtinen PL, Hyödynmaa S.

Rep Pract Oncol Radiother. 2015 Jul-Aug;20(4):292-8. doi: 10.1016/j.rpor.2015.03.002. Epub 2015 Apr 1.

Supplemental Content

Loading ...
Support Center